CHA2DS2-VASc and readmission with new-onset atrial fibrillation, atrial flutter, or acute cerebrovascular accident
Rutland J, Ayoub K, Etaee F, Ogunbayo G, Darrat Y, Marji M, Masri A, Elayi C. CHA2DS2-VASc and readmission with new-onset atrial fibrillation, atrial flutter, or acute cerebrovascular accident. International Journal Of Cardiology 2020, 323: 72-76. PMID: 32800906, DOI: 10.1016/j.ijcard.2020.08.027.Peer-Reviewed Original ResearchMeSH KeywordsAtrial FibrillationAtrial FlutterHumansPatient ReadmissionRetrospective StudiesRisk FactorsStrokeConceptsAF/atrial flutterAcute cerebrovascular accidentCerebrovascular accidentAtrial flutterAtrial fibrillationIndex hospitalizationAtrial arrhythmiasNew-onset atrial fibrillationOverall re-admission rateNew-onset atrial arrhythmiasPrior atrial arrhythmiaLarge contemporary cohortNationwide Readmissions DatabaseRe-admission ratesMonths of hospitalizationVASc risk scoreCHA2DS2-VAScCause mortalityReadmission ratesSecondary outcomesHospital readmissionHospitalized patientsPrimary outcomeContemporary cohortStudy cohortDigoxin, mortality, and cardiac hospitalizations in patients with atrial fibrillation and heart failure with reduced ejection fraction and atrial fibrillation: An AF-CHF analysis
Elayi C, Shohoudi A, Moodie E, Etaee F, Guglin M, Roy D, Khairy P, Investigators A. Digoxin, mortality, and cardiac hospitalizations in patients with atrial fibrillation and heart failure with reduced ejection fraction and atrial fibrillation: An AF-CHF analysis. International Journal Of Cardiology 2020, 313: 48-54. PMID: 32320783, DOI: 10.1016/j.ijcard.2020.04.047.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Arrhythmia AgentsAtrial FibrillationDigoxinHeart FailureHospitalizationHumansStroke VolumeConceptsReduced ejection fractionAtrial fibrillationCardiovascular hospitalizationEjection fractionImpact of digoxinArrhythmic deathHazard ratioHeart failureCongestive Heart Failure trialAF-CHF trialsHeart Failure TrialSafety of digoxinSubgroup of patientsMarginal structural modelingCardiovascular causesCause mortalityCardiac hospitalizationSecondary outcomesFailure TrialClinical benefitHospitalizationPatientsDigoxinFibrillationOne-yearRandomized trial comparing the effectiveness of internal (through implantable cardioverter defibrillator) versus external cardioversion of atrial fibrillation
Elayi C, Parrott K, Etaee F, Shah J, Leung S, Guglin M, Elayi E, Jessinger M, Ogunbayo G, Catanzaro J, Morales G, Darrat Y. Randomized trial comparing the effectiveness of internal (through implantable cardioverter defibrillator) versus external cardioversion of atrial fibrillation. Journal Of Interventional Cardiac Electrophysiology 2020, 58: 261-267. PMID: 31927665, DOI: 10.1007/s10840-019-00689-7.Peer-Reviewed Original ResearchMeSH KeywordsAtrial FibrillationDefibrillators, ImplantableElectric CountershockFemaleHumansInfant, NewbornMaleTreatment OutcomeConceptsExternal direct current cardioversionImplantable cardioverter defibrillatorSymptomatic atrial fibrillationDirect current cardioversionAtrial fibrillationCardioversion groupPrimary endpointCurrent cardioversionInternal cardioversionBiventricular implantable cardioverter defibrillatorBaseline clinical characteristicsResultsThirty-one patientsNon-ischemic cardiomyopathyConclusionAmong patientsClinical characteristicsFirst shockConsecutive patientsExternal cardioversionMean ageSinus rhythmCardioverter defibrillatorCardioversionPatientsSignificant differencesFibrillation